Gross Margin: A company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage. Calculated as: Gross Income / Total Revenues
Spyre Therapeutics, Inc. (SYRE) Gross Margin data is not available for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-44.77M |
|
-- |
|
-- |
|
$53.57M |
|
$-53.57M |
|
$8.78M |
|
$-44.79M |
|
$-44.79M |
|
$-44.77M |
|
$-44.77M |
|
$-44.77M |
|
$-44.77M |
|
$-53.57M |
|
$-53.57M |
|
60.27M |
|
60.27M |
|
$-0.60 |
|
$-0.60 |
|
| Balance Sheet Financials | |
$569.77M |
|
-- |
|
$0.01M |
|
$569.78M |
|
$70.68M |
|
-- |
|
$16.49M |
|
$87.17M |
|
$326.79M |
|
$482.61M |
|
$482.61M |
|
60.28M |
|
| Cash Flow Statement Financials | |
$-40.99M |
|
$-0.06M |
|
$0.12M |
|
$89.42M |
|
$48.49M |
|
$-40.93M |
|
$8.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Gross Margin |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-40.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.70% |
|
-9.28% |
|
-7.86% |
|
-9.28% |
|
$8.01 |
|
$-0.68 |
|
$-0.68 |
|